Product Description
Netupitant is a highly selective neurokinin-1 receptor antagonist and palonosetron is a serotonin 5-HT3 receptor antagonist with a distinct pharmacological profile. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/26613606/)
Mechanisms of Action: NK1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Chile | Croatia | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Germany | Hong Kong | Hungary | India | Indonesia | Malaysia | Mexico | Netherlands | New Zealand | Norway | Philippines | Russia | South Africa | Spain | Taiwan | Tunisia | United Arab Emirates | United Kingdom | United States | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Helsinn Healthcare
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Brazil, France, Italy, Poland, Spain, United States
Active Clinical Trial Count: 8
Highest Development Phases
Phase 3: Nose Cancer
Phase 2: Breast Cancer|Central Nervous System Cancer|Cervical Cancer|Fallopian Tube Cancer|Lymphoma|Motion Sickness|Ovarian Cancer|Peritoneal Cancer|Pregnancy Outcomes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ZNâc3-005 | P2 |
Recruiting |
Fallopian Tube Cancer|Peritoneal Cancer|Ovarian Cancer |
2027-09-01 |
|
| SWC999 | P2 |
Recruiting |
Motion Sickness|Pregnancy Outcomes|Central Nervous System Cancer |
2023-12-31 |
|
| NCI-2017-00599 | P3 |
Completed |
Nose Cancer |
2022-02-14 |
|
| OLNEPA | P2 |
Completed |
Breast Cancer|Nose Cancer |
2021-12-17 |